LinkedInXFacebook
Subscribe
Orthopedics This Week
  • My Feed
  • |Posts
  • |Events
  • |MSK Innovations
  • |Power Rankings
  • |Masterclasses
  • |Technology Awards
  • Press Releases
  • |Advertising
  • |Job Board
  • Spine
  • ◆Joints
  • ◆Upper Extremities
  • ◆Foot & Ankle
  • ◆Sports Medicine
  • ◆Pain Mgmt
  • ◆Trauma
  • ◆Biologics
  • ◆Technology
  • ◆People
  • ◆Company News
  • ◆Legal & Regulatory
Home/Company News/Symmetry: 510(k) Clearance for Evolution Valve
Company News

Symmetry: 510(k) Clearance for Evolution Valve

August 30, 2012 1 min read Premium comments

Advertisement

Symmetry: 510(k) Clearance for Evolution Valve
Courtesy Symmetry Medical Inc.
Secondary

Symmetry Medical Inc. has announced that it received FDA 510(k) clearance for its FLASH PAK Evolution valve. The Evolution valve is the next generation valve for Symmetry’s market leading, immediate use (flash) sterilization product, FLASH PAK, and is distributed exclusively through Symmetry Surgical. The patent pending stainless steel construction of the new valve is designed for ease of use and simplicity of care.

Chris Huntington, chief operating officer of Symmetry Surgical, said in the August 28, 2012 news release, “Making care and maintenance of our products easy is a key mission of Symmetry Surgical. The Evolution valve brings a new level of innovation to our market leading FLASH PAK; a product that clinicians have grown to depend on for over 20 years.”

Huntington told OTW,

Evolution is the next generation valve for our FLASH PAK sterilization product, controlling airflow into and out of the system. Once the valve is closed, it does not allow ambient air in, nor does it allow air out, thus keeping the sterility of the items in the container intact. In designing and developing the Evolution valve, we focused on enhancing both ease of use and simplicity of maintenance, which were top voice of the customer requirements. We also wanted to ensure that our new valve was backwards compatible with our existing FLASH PAK product.

React:

Discussion

14
DS
Dr. Sarah MitchellOrthopedic Surgeon · Mayo Clinic

This is a fascinating development. In my practice we've seen similar outcomes with the revised protocol. The key differentiator seems to be patient selection criteria. Has anyone else noticed the correlation with BMI thresholds?

8
JT
James Thornton, MDSpine Fellow · HSS

Great point. I'd push back slightly on the conclusion, the sample size in the cited study is too small to draw population-level inferences. That said, the directional signal is compelling and worth a larger RCT.

5
RP
R. PatelSports Medicine · Stanford

We implemented a similar approach last year. Early results are promising but we're still gathering 12-month follow-up data. Happy to share our protocol if anyone is interested.

Join the conversation

Orthopedic professionals are discussing this. Sign in and upgrade to read every comment and add your voice.

Subscribe

Get Full Access

Read every OTW article and join member discussions for $24.99/month.

Get Full Access

Advertisement

Advertisement

Advertisement

Orthopedics This Week

The most trusted source in orthopedic industry news since 2005. Covering spine, joints, trauma, biologics, and the business of orthopedics.

A publication of RRY Publications, LLC

LinkedInXFacebook

Categories

  • Spine
  • Joints
  • Upper Extremities
  • Foot & Ankle
  • Sports Medicine
  • Pain Mgmt
  • Trauma
  • Biologics
  • Technology
  • People
  • Company News
  • Legal & Regulatory

Resources

  • Subscribe
  • Community Posts
  • Job Board
  • Press Release Opportunities
  • Power Rankings
  • About OTW
  • Advertise
  • Contact Us

Get Full Access

Unlimited articles, community posts, and Power Rankings.

Get Full Access

Plans start at $24.99/mo · Annual saves 20%

© 2026 Orthopedics This Week · RRY Publications, LLC

Privacy PolicyTerms of ServiceCookie Policy